Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2007 March; 8(1): E177–E185.
Published online 2007 March 30. doi:  10.1208/pt0801026
PMCID: PMC2750437

Development of a peptide-containing chewing gum as a sustained release antiplaque antimicrobial delivery system


The objective of this study was to characterize the stability of KSL-W, an antimicrobial decapeptide shown to inhibit the growth of oral bacterial strains associated with caries development and plaque formation, and its potential as an antiplaque agent in a chewing gum formulation. KSL-W formulations with or without the commercial antibacterial agent cetylpyridinium chloride (CPC) were prepared. The release of KSL-W from the gums was assessed in vitro using a chewing gum apparatus and in vivo by a chew-out method. A reverse-phase high-performance liquid chromatography method was developed for assaying KSL-W. Raw material stability and temperature and pH effects on the stability of KSL-W solutions and interactions of KSL-W with tooth-like material, hydroxyapatite discs, were investigated.

KSL-W was most stable in acidic aqueous solutions and underwent rapid hydrolysis in base. It was stable to enzymatic degradation in human saliva for 1 hour but was degraded by pancreatic serine proteases. KSL-W readily adsorbed to hydroxyapatite, suggesting that it will also adsorb to the teeth when delivered to the oral cavity. The inclusion of CPC caused a large increase in the rate and extent of KSL-W released from the gums. The gum formulations displayed promising in vitro/ in vivo release profiles, wherein as much as 90% of the KSL-W was released in a sustained manner within 30 minutes in vivo. These results suggest that KSL-W possesses the stability, adsorption, and release characteristics necessary for local delivery to the oral cavity in a chewing gum formulation, there-by serving as a novel antiplaque agent.

Keywords: KSL-W, chewing gum, sustained release, cetylpyridinium chloride, antiplaque, antimicrobial, peptide, stability

Full Text

The Full Text of this article is available as a PDF (333K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Paster BJ, Olsen I, Aas JA, Dewhirst FE. The breadth of bacterial diversity in the human periodontal pocket and other oral sites. Periodontol 2000. 2006;42:80–87. doi: 10.1111/j.1600-0757.2006.00174.x. [PubMed] [Cross Ref]
2. Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial oral cavity. J Clin Microbiol. 2005;43:5721–5732. doi: 10.1128/JCM.43.11.5721-5732.2005. [PMC free article] [PubMed] [Cross Ref]
3. Marsh PD. Dental plaque as a biofilm and a microbial community: implications for health and disease. BMC Oral Health. 2006;6:14–14. doi: 10.1186/1472-6831-6-S1-S14. [PMC free article] [PubMed] [Cross Ref]
4. Holt RL. Studies on human dental plaque. 1. Physical and chemical characteristics and enzyme activities of pooled plaque extracts. J Oral Pathol. 1975;4:73–85. doi: 10.1111/j.1600-0714.1975.tb01855.x. [PubMed] [Cross Ref]
5. Scheie AA, Fejerskov O, Danielsen B. The effects of xylitol-containing chewing gums on dental plaque and acidogenic potential. Int Dent J. 1994;46:91–96. [PubMed]
6. Papanaou PN. Microbial markers of periodontal diseases. In: Busscher HJ, Evans LV, editors. Oral Biofilms and Plaque Controls. Amsterdam, The Netherlands: Harwood Academic Publishers; 1999. pp. 205–220.
7. Olsson J, van der Heijde Y, Holmberg K. Plaque formation in vivo and bacterial attachment in vitro on permanently hydrophobic and hydrophilic surfaces. Caries Res. 1992;26:428–433. doi: 10.1159/000261482. [PubMed] [Cross Ref]
8. Gibbons RJ. Bacterial adhesion to oral tissues: a model for infectious diseases. J Dent Res. 1989;68:750–760. [PubMed]
9. Marsh PD. Microbial ecology of dental plaque and its significance in health and disease. Adv Dent Res. 1994;8:263–271. [PubMed]
10. Concannon SP, Crowe TD, Abercrombie JJ, et al. Susceptibility of oral bacteria to an antimicrobial decapeptide. J Med Microbiol. 2003;52:1083–1093. doi: 10.1099/jmm.0.05286-0. [PubMed] [Cross Ref]
11. Wilson M. Susceptibility of oral bacterial biofilms to antimicrobial agents. J Med Microbiol. 2007;44:79–87. doi: 10.1099/00222615-44-2-79. [PubMed] [Cross Ref]
12. Leung KP, Crowe TD, Abercrombie JJ, et al. Control of oral biofilm formation by an antimicrobial decapeptide. J Dent Res. 2005;84:1172–1177. [PubMed]
13. Na DH, Faraj J, Capan Y, Leung KP, DeLuca PP. Chewing gum of antimicrobial decapeptide (KSL) as a sustained antiplaque agent: preformulation study. J Control Release. 2005;107:122–130. doi: 10.1016/j.jconrel.2005.05.027. [PubMed] [Cross Ref]
14. Na DH, Faraj J, Capan Y, Leung KP, DeLuca PP. Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity.Pharm Res. In press. [PubMed]
15. Bonesvoll P, Lokken P, Rolla G, Paus PN. Retention of chlorhexidine in the human oral cavity after mouth rinses. Arch Oral Biol. 1974;19:209–212. doi: 10.1016/0003-9969(74)90263-5. [PubMed] [Cross Ref]
16. Ainamo J, Etemadzadeh H. Prevention of plaque growth with chewing gum containing chlorhexidine acetate. J Clin Periodontol. 1987;14:524–527. doi: 10.1111/j.1600-051X.1987.tb00994.x. [PubMed] [Cross Ref]
17. Rassing MR. Chewing gum as a drug delivery system. Adv Drug Deliv Rev. 1994;13:89–121. doi: 10.1016/0169-409X(94)90028-0. [Cross Ref]
18. Jenssen ME, Lokind KB. Chewing gum as a drug delivery system: influence of additives upon the rate of release metronidazole and propranolol hydrochloride from chewing gum. Farm Sci Ed. 1988;16:94–97.
19. Yang X, Wang G, Zhang X. Release kinetics of catechines from chewing gum. J Pharm Sci. 2004;93:293–299. doi: 10.1002/jps.10564. [PubMed] [Cross Ref]
20. Krook M, Lindbladh C, Eriksen JA, Mosbach K. Selection of a cyclic nonapeptide inhibitor to α-chymotripsin using a phage display peptide library. Mol Divers. 1997;3:149–159. doi: 10.1023/A:1009697515328. [PubMed] [Cross Ref]
21. Kvist C, Andersson SB, Fors S, Wennergren B, Berglund J. Apparatus for studying in vitro drug release from medicated chewing gums. Int J Pharm. 1999;189:57–65. doi: 10.1016/S0378-5173(99)00236-7. [PubMed] [Cross Ref]
22. Rassing MR. Specialized oral mucosal drug delivery systems: chewing gums. In: Rathbone MJ, editor. Oral Mucosal Drug Delivery. New York, NY: Marcel Dekker; 2007. pp. 319–357.
23. Rolla G, Loe H, Schiott CR. Affinity of chlorhexidine to hydroxyapatite and to salivary mucins. J Periodontal Res. 1970;5:90–95. doi: 10.1111/j.1600-0765.1970.tb00698.x. [PubMed] [Cross Ref]
24. Rolla G, Loe H, Schiott CR. The retention of chlorhexidine in the human oral cavity. Arch Oral Biol. 1971;16:1109–1116. doi: 10.1016/0003-9969(71)90215-9. [PubMed] [Cross Ref]
25. Emilson CG, Erickson T, Heyden G, Magnusson BC. Uptake of chlorhexidine to hydroxyapatite. J Periodontal Res. 1973;8:17–21. doi: 10.1111/j.1600-0765.1973.tb02159.x. [PubMed] [Cross Ref]
26. Charles CH, Mostler KM, Bartels LL, Mankodi SM. Comparative anti-plaque and antigingivitis effectiveness of a chlorhexidine and an essential oil mouth rinse: 6-month clinical trial. J Clin Periodontol. 2004;31:878–884. doi: 10.1111/j.1600-051X.2004.00578.x. [PubMed] [Cross Ref]
27. Ehara A, Torii M, Imazato S, Ebisu S. Antibacterial activities and release kinetics of a newly developed recoverable controlled agent-release system. J Dent Res. 2000;79:824–828. [PubMed]
28. Siewert M, Dressman J, Brown CK, Shah VP. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms.AAPS PharmSciTech. 2003;4:Article 7. [PMC free article] [PubMed]
29. Lif Holgerson P, Stecksen-Blicks C, Sjostrom I, Twetman S. Effect of xylitol-containing chewing gums on interdental plaque: pH in habitual xylitol consumers. Acta Odontol Scand. 2005;63:233–238. doi: 10.1080/00016350510019883. [PubMed] [Cross Ref]
30. Soderling E, Trahan L, Tammiala-Salonen T, Hakkinen L. Effect of xylitol, xylitol-sorbitol and placebo chewing gums on the plaque of habitual xylitol consumers. Eur J Oral Sci. 1997;105:170–177. doi: 10.1111/j.1600-0722.1997.tb00196.x. [PubMed] [Cross Ref]
31. Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthet Dent. 2001;85:162–169. doi: 10.1067/mpr.2001.113778. [PubMed] [Cross Ref]
32. Herrera D, Santos S, Ferrus J, Barbieri G, Trombelli L, Sanz M. Efficacy of a 0.15% benzydamine hydrochloride and 0.05% cetylpyridinium chloride mouth rinse on 4-day de novo plaque formation. J Clin Periodontol. 2005;32:595–603. doi: 10.1111/j.1600-051X.2005.00718.x. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists